SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001437749-20-023829
Filing Date
2020-11-13
Accepted
2020-11-13 16:06:06
Documents
66
Period of Report
2020-09-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q navb20200930_10q.htm 10-Q 1380367
2 EXHIBIT 31.1 ex_212346.htm EX-31.1 9509
3 EXHIBIT 32.1 ex_212347.htm EX-32.1 4924
  Complete submission text file 0001437749-20-023829.txt   7448054

Data Files

Seq Description Document Type Size
4 XBRL INSTANCE DOCUMENT navb-20200930.xml EX-101.INS 1566797
5 XBRL TAXONOMY EXTENSION SCHEMA navb-20200930.xsd EX-101.SCH 58183
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE navb-20200930_cal.xml EX-101.CAL 41786
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE navb-20200930_def.xml EX-101.DEF 505864
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE navb-20200930_lab.xml EX-101.LAB 372656
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE navb-20200930_pre.xml EX-101.PRE 524020
Mailing Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017
Business Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000810509 (see all company filings)

IRS No.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35076 | Film No.: 201311487
SIC: 2835 In Vitro & In Vivo Diagnostic Substances